Gilead scraps lead arthritis drug from $405M MiroBio buyout in latest blow to BTLA agonist field

Gilead has abandoned work on the lead drug from its $405 million buyout of MiroBio in the latest blow to the BTLA agonist field. Gilead has abandoned work on the lead rheumatoid arthritis drug from its $405 million buyout of MiroBio in the latest blow to the BTLA agonist field. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation Awards Resources…

Source: FierceBiotech